In a nutshell This study evaluated the risk of cardiovascular (CV; heart and blood vessels) side effects in cancer patients treated with PD-1/PD-L1 inhibitors. The data showed that PD-1/PD-L1 inhibitors alone or combined with chemotherapy significantly increased the risk of CV side effects. PD-1/PD-L1 inhibitors combined with chemotherapy significantly...
Read More
In a nutshell This study aimed to investigate the effectiveness and safety of combining pembrolizumab (PEM; Keytruda)) and ipilimumab (IPI; Yervoy) for the treatment of advanced-stage melanoma in patients that have progressed after previous PD-1/L1 therapy. The study concluded that this combination was well tolerated and improved the...
Read More
In a nutshell This trial is looking at the effectiveness, safety, and tolerability of ladiratuzumab vedotin (LV) in patients with advanced solid tumors, including melanoma. The main outcome to be measured in this trial is the response rate to the new drug. The details Advanced tumors have spread from the organ where they originated....
Read More
In a nutshell This study was carried out to assess whether immune related side effects (IRSE) of anti-PD1 therapy affect the survival of patients with advanced melanoma. The authors of this study found that patients who had IRSE had better outcomes. Some background Advanced melanoma is a form of skin cancer that comes from a cell called a...
Read MoreIn a nutshell This article reviewed the types and frequency of different skin-related side effects that patients with melanoma experience while receiving biological treatments. Some background Treatment for patients with melanoma has changed in recent years from chemotherapy to biological therapies. Biological therapies include BRAF inhibitors...
Read More
In a nutshell This study evaluated the quality of life for survivors of melanoma who received immunotherapy. This study found that melanoma survivors had a significantly lower quality of life compared to the general population. Some background Immune checkpoint inhibitors are a new class of anti-cancer drugs that take advantage of the...
Read MoreIn a nutshell This trial aims to look at how safe and effective a new combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda). The main outcome measured will be the number of patients who respond to treatment, and to what extent they respond. This study is being conducted in Spain, Sweden, and the United States. The details...
Read More
In a nutshell This study wanted to find out if patients with melanoma who had immune system side effects after treatment with nivolumab (Opdivo) had better outcomes than patients without side effects. The study found that the patients who had side effects from using nivolumab ended up with better responses to treatment and...
Read More
In a nutshell This study investigated whether levels of S100B and lactate dehydrogenase (LDH) in patients with melanoma treated with immunotherapy has any relationship to survival. The study found that increased levels of S100B and LDH were associated with reduced survival in patients with melanoma treated with certain immunotherapies. Some background...
Read More
In a nutshell This study investigated whether the risk of developing melanoma brain metastases (MBM) and survival among patients with MBM has changed since the introduction of more effective therapies. The results found the overall survival for patients with MBM has improved significantly since 2011. Some background In more than 33% of patients...
Read More
In a nutshell This study investigated the effect of nivolumab (Opdivo) in patients with progressive melanoma after ipilimumab (Yervoy) treatment. Researchers suggested that nivolumab treatment is associated with better response compared with chemotherapy. Some background Recent new therapies, such as immunotherapy, have changed the treatment of...
Read More
In a nutshell The authors reviewed the treatment-related side effects associated with ipilimumab (Yervoy), pembrolizumab (Keytruda), and nivolumab (Opdivo) in melanoma. The authors found that a higher dose of ipilimumab was correlated with more side effects, but the same was not true for pembrolizumab and nivolumab. Some background In advanced...
Read More
